281 related articles for article (PubMed ID: 35412608)
21. IFN-beta and EIF2AK2 are potential biomarkers for interstitial lung disease in anti-MDA5 positive dermatomyositis.
Liu Y; Feng S; Liu X; Tang Y; Li X; Luo C; Tao J
Rheumatology (Oxford); 2023 Nov; 62(11):3724-3731. PubMed ID: 36912714
[TBL] [Abstract][Full Text] [Related]
22. Proteomic profiling identifies SPP1 associated with rapidly progressive interstitial lung disease in anti-MDA5-positive dermatomyositis.
Qiu Y; Feng X; Liu C; Shi Y; Xu L; You H; Wang L; Lv C; Wang F; Tan W
Arthritis Res Ther; 2024 Jan; 26(1):9. PubMed ID: 38167532
[TBL] [Abstract][Full Text] [Related]
23. Coexistence of Anti-Ro52 Antibodies in Anti-MDA5 Antibody-Positive Dermatomyositis Is Highly Associated With Rapidly Progressive Interstitial Lung Disease and Mortality Risk.
Lv C; You H; Xu L; Wang L; Yuan F; Li J; Wu M; Zhou S; Da Z; Qian J; Wei H; Yan W; Zhou L; Wang Y; Yin S; Zhou D; Wu J; Lu Y; Su D; Liu Z; Liu L; Ma L; Xu X; Zang Y; Liu H; Ren T; Wang F; Zhang M; Tan W
J Rheumatol; 2023 Feb; 50(2):219-226. PubMed ID: 35705235
[TBL] [Abstract][Full Text] [Related]
24. The clinical characteristics of subcutaneous and mediastinal emphysema in anti-melanoma differentiation-associated 5 positive dermatomyositis associated with interstitial lung disease.
Huang W; Chen D; Ren F; Luo L; Zhou J; Huang D; Tian M; Qian K; Jiang Y; Tang L
Clin Exp Rheumatol; 2024 Feb; 42(2):262-268. PubMed ID: 38147317
[TBL] [Abstract][Full Text] [Related]
25. Relevance of leukaemia inhibitory factor to anti-melanoma differentiation-associated gene 5 antibody-positive interstitial lung disease.
Ichimura Y; Ikei H; Konishi R; Zeniya M; Okai T; Nomura T; Negishi K; Okiyama N
Rheumatology (Oxford); 2023 Jun; 62(6):2267-2271. PubMed ID: 36326445
[TBL] [Abstract][Full Text] [Related]
26. Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody.
Jiang L; Wang Y; Peng Q; Shu X; Wang G; Wu X
Clin Rheumatol; 2019 Jun; 38(6):1655-1663. PubMed ID: 30739212
[TBL] [Abstract][Full Text] [Related]
27. [Clinical characteristics and prognostic factors of patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis associated interstitial lung disease].
Zou RY; Zhao Q; Tian YQ; Yan X; Qiu XH; Gao YJ; Liu Y; Huang M; Cao M; Dai JH; Cai HR
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Aug; 46(8):781-790. PubMed ID: 37536988
[No Abstract] [Full Text] [Related]
28. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review.
Huang K; Vinik O; Shojania K; Yeung J; Shupak R; Nimmo M; Avina-Zubieta JA
Rheumatol Int; 2019 Nov; 39(11):1971-1981. PubMed ID: 31375890
[TBL] [Abstract][Full Text] [Related]
29. Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis.
Peng Y; Zhang S; Zhao Y; Liu Y; Yan B
Clin Rheumatol; 2018 Jan; 37(1):107-115. PubMed ID: 28842784
[TBL] [Abstract][Full Text] [Related]
30. Gender differences in patients with anti-MDA5-positive dermatomyositis: a cohort study of 251 cases.
Cheng L; Xu L; Xu Y; Yuan F; Li J; Wu M; Da Z; Wei H; Zhou L; Yin S; Wu J; Lu Y; Su D; Liu Z; Liu L; Ma L; Xu X; Liu H; Ren T; Zang Y
Clin Rheumatol; 2024 Jan; 43(1):339-347. PubMed ID: 37985533
[TBL] [Abstract][Full Text] [Related]
31. WDFY4 polymorphisms in Chinese patients with anti-MDA5 dermatomyositis is associated with rapid progressive interstitial lung disease.
Guo L; Zhang X; Pu W; Zhao J; Wang K; Zhang D; Hong S; Ma Y; Wang X; Ye S; Guo Q; Wang J
Rheumatology (Oxford); 2023 Jun; 62(6):2320-2324. PubMed ID: 36637178
[TBL] [Abstract][Full Text] [Related]
32. Evaluating the value of superoxide dismutase in anti-MDA5-positive dermatomyositis associated with interstitial lung disease.
Huang W; Chen D; Wang Z; Ren F; Luo L; Zhou J; Huang D; Tian M; Chen H; Tang L
Rheumatology (Oxford); 2023 Mar; 62(3):1197-1203. PubMed ID: 35866990
[TBL] [Abstract][Full Text] [Related]
33. Rapidly progressive interstitial lung disease risk prediction in anti-MDA5 positive dermatomyositis: the CROSS model.
Wang L; Lv C; You H; Xu L; Yuan F; Li J; Wu M; Zhou S; Da Z; Qian J; Wei H; Yan W; Zhou L; Wang Y; Yin S; Zhou D; Wu J; Lu Y; Su D; Liu Z; Liu L; Ma L; Xu X; Zang Y; Liu H; Ren T; Liu J; Wang F; Zhang M; Tan W
Front Immunol; 2024; 15():1286973. PubMed ID: 38361940
[TBL] [Abstract][Full Text] [Related]
34. Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD.
Horiike Y; Suzuki Y; Fujisawa T; Yasui H; Karayama M; Hozumi H; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Ogawa N; Suda T
Rheumatology (Oxford); 2019 Dec; 58(12):2143-2152. PubMed ID: 31143953
[TBL] [Abstract][Full Text] [Related]
35. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.
Motegi SI; Sekiguchi A; Toki S; Kishi C; Endo Y; Yasuda M; Ikeuchi H; Sakairi T; Hara K; Yamaguchi K; Maeno T; Hiromura K; Ishikawa O
Eur J Dermatol; 2019 Oct; 29(5):511-517. PubMed ID: 31617496
[TBL] [Abstract][Full Text] [Related]
36. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM.
Koga T; Fujikawa K; Horai Y; Okada A; Kawashiri SY; Iwamoto N; Suzuki T; Nakashima Y; Tamai M; Arima K; Yamasaki S; Nakamura H; Origuchi T; Hamaguchi Y; Fujimoto M; Ishimatsu Y; Mukae H; Kuwana M; Kohno S; Eguchi K; Aoyagi K; Kawakami A
Rheumatology (Oxford); 2012 Jul; 51(7):1278-84. PubMed ID: 22378718
[TBL] [Abstract][Full Text] [Related]
37. Predictors of Poor Outcome of Anti-MDA5-Associated Rapidly Progressive Interstitial Lung Disease in a Chinese Cohort with Dermatomyositis.
Li Y; Li Y; Wu J; Miao M; Gao X; Cai W; Shao M; Zhang X; Xu Y; Cong L; He J; Sun X
J Immunol Res; 2020; 2020():2024869. PubMed ID: 33299896
[TBL] [Abstract][Full Text] [Related]
38. MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 pandemic (MIP-C).
David P; Sinha S; Iqbal K; De Marco G; Taheri S; McLaren E; Maisuria S; Arumugakani G; Ash Z; Buckley C; Coles L; Hettiarachchi C; Payne E; Savic S; Smithson G; Slade M; Shah R; Marzo-Ortega H; Keen M; Lawson C; Mclorinan J; Nizam S; Reddy H; Sharif O; Sultan S; Tran G; Wood M; Wood S; Ghosh P; McGonagle D
EBioMedicine; 2024 Jun; 104():105136. PubMed ID: 38723554
[TBL] [Abstract][Full Text] [Related]
39. Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis.
Wu W; Guo L; Fu Y; Wang K; Zhang D; Xu W; Chen Z; Ye S
Clin Rev Allergy Immunol; 2021 Apr; 60(2):293-304. PubMed ID: 33405101
[TBL] [Abstract][Full Text] [Related]
40. Clinical features and immune-related protein patterns of anti-MDA5 positive clinically amyopathic dermatomyositis Dutch patients.
Hensgens MPM; Delemarre EM; Drylewicz J; Voortman M; Krol RM; Dalm VASH; Miedema JR; Wiertz I; Grutters J; Limper M; Nierkens S; Leavis HL
Rheumatology (Oxford); 2022 Oct; 61(10):4087-4096. PubMed ID: 35048953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
